IP Library Granted Patent US 8,987,498
Granted Patent B2
US 8,987,498 · App. 13/699,585 · Granted Mar 24, 2015

Enantiomerically pure amines

Inventors: Rosemarie Riedl (Vienna, AT); Werner Heilmayer (Zillingtal, AT); Lee Spence (Vienna, AT); Atchyuta Rama Chandra Murty Bulusu (Perchtoldsdorf, AT)
Assignee: Nabriva Therapeutics AG
C07C271/24C07C61/22C07C211/40C07C247/22C07C265/10C07C323/41C07C323/43C07C327/30C07D303/36C07C231/12C07C231/14C07C233/63C07C269/04C07C269/06C07C2101/14C07C2101/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,498
App. No.
13/699,585
Granted
Mar 24, 2015
Kind
B2
Abstract

A compound of formula wherein PROT is an amine protecting group and PROT′ is hydrogen; or PROT and PROT′ together with the nitrogen atom to which they are attached form a heterocyclic ring as an amine protecting group, and PROT″ is a thiol protecting group, processes for its production, intermediates in their production and production of intermediates in stereoisomerically pure form, and their use for the production of pharmaceutically active compounds.

Claims (135)

1. A compound of formula I

wherein

PROT is selected from

ethoxycarbonyl,

2,2,2-trifluoroacetyl, and

PROT′ is hydrogen; or

PROT and PROT′ together with the nitrogen atom to which they are attached form a heterocyclic ring as an amine protecting group, and

PROT″ is a thiol protecting group.

2. A compound according to claim 1 , wherein

PROT is selected from

ethoxycarbonyl,

2,2,2-trifluoroacetyl, and

PROT′ is hydrogen.

3. A compound according to claim 1 , wherein PROT and PROT′ together with the nitrogen atom to which they are attached form phthalimido-N-yl.

4. A compound according to claim 1 , wherein PROT″ is benzoyl or trityl.

5. A compound according to claim 1 , wherein the compound is of formula

wherein PROT is selected from

ethoxycarbonyl,

2,2,2-trifluoroacetyl, and.

6. A compound according to claim 5 , which is of formula

wherein R together with the C═O to which it is attached is ethoxycarbonyl or 2,2,2-trifluoroacetyl.

7. A compound according to claim 1 , selected from the group consisting of:

{(1R, 2R, 4R)-4-[(2,2,2-Trifluoro-acetyl)-amino]-2-hydroxy-cyclohexyl}-benzene-carbothioate,

tert-Butyl [(1R, 3R, 4R)-3-hydroxy-4-tritylsulfanyl-cyclohexyl]-carbamate, and

2,2,2-Trifluoro-N-((1R, 3R, 4R)-3-hydroxy-4-tritylsulfanyl-cyclohexyl)-acetamide.

8. A compound according to claim 1 , which is of formula

9. A process for the preparation of a compound of formula I according to claim 1 , comprising

performing oxiran ring opening in a compound of formula

or in a compound of formula

or in a compound of formula

or in a compound of formula

respectively, wherein PROT, PROT′ and R are as defined in claim 1 ,

optionally by reaction with an optionally protected or activated thiol,

isolating a compound of formula I in the form of a single regioisomer and a single diastereomer from the reaction mixture;

wherein optionally a compound of formula II, II S , II SS or II SSS is obtained by epoxidation of the double bond in a compound of formula

and

isolating a compound formula II, II S , II SS or II SSS , wherein PROT, PROT′ and R are as defined in claim 1 , obtained from the reaction mixture.

10. A process according to claim 9 wherein formula II, IIs, IIss or IIsss is selected from the group consisting of

tert-Butyl (1R, 3R, 6R)-(7-oxa-bicyclo[4.1.0]hept-3-yl)-carbamate, and

2,2,2-Trifluoro-N-(1R, 3R, 6S)-(7-oxa-bicyclo[4.1.0]hept-3-yl)-acetamide.

11. A process for the production of a compound of formula I according to claim 1 , wherein PROT′ is hydrogen, comprising

a) either reacting a compound of formula

with an azidoyl forming agent, optionally diphenylphosphoryl azide, optionally in the presence of a base, or

reacting compound of formula V with an acid chloride forming agent, optionally oxalyl chloride or thionyl chloride, to obtain a compound of formula IX

and

further reacting a compound of formula IX with sodium azide, to obtain the acyl azide of formula

b) subjecting the acyl azide of formula VI to a Curtius rearrangement to obtain an isocyanate of formula

c) either reacting the isocyanate of step b) either via addition of an alcohol or via reaction with an strong organic acid and optionally in the presence of CuCl, or

subjecting a compound of formula VII to hydrolysis with subsequent loss of carbon dioxide to obtain a compound of formula IV

and

further reacting a compound of formula IV with an amino protecting group, optionally in the presence of base, to obtain a compound of formula III, III S , III SS or III SSS , respectively,

wherein PROT and R are as defined in claim 1 and PROT′ is hydrogen,

d) subjecting a compound of formula III, III S , III SS or III SSS , respectively, to epoxidation by use of an oxidation agent to obtain a corresponding oxiran of formula II, II S , II SS or II SSS , respectively,

wherein PROT, PROT′ and R are as defined in claim 1 , and PROT′ is hydrogen, in solution,

e) subjecting a compound obtained in step d) to oxiran ring opening under introduction of a sulfur group in the side chain of the cyclohexyl ring via a sulfur donating agent, and

f) directly isolating a compound of formula I according to claim 1 , wherein PROT, PROT″ and R are as defined in claim 1 , and PROT′ is hydrogen,

optionally by addition of an appropriate anti solvent,

optionally whereby the reaction a) to e) is performed in a single solvent (system), and/or whereby none of the intermediates obtained in a) to d) is isolated, and

isolating a compound of formula I in the form of a crystalline solid, from the reaction mixture.

12. A process according to claim 11 , wherein none of the intermediates obtained in a) to d) is isolated.

13. A process according to claim 11 , wherein the reaction a) to e) is performed in a single solvent (system).

14. A process for the preparation of a compound of formula I S according to claim 5 , comprising

performing oxiran ring opening in a compound of formula

wherein PROT is an amine protective group,

optionally by reaction with an optionally protected or activated thiol, and isolating a compound of formula in the form of a single regioisomer and a single diastereomer from the reaction mixture;

wherein optionally the compound of formula II S is obtained by epoxidation of the double bond in a compound of formula

wherein PROT is an amine protecting group, and

isolating a compound formula II S obtained from the reaction mixture.

15. A process for the preparation of a compound of formula I SS according to claim 6 , comprising

performing oxiran ring opening in a compound of formula

wherein R is as defined in claim 6 ,optionally by reaction with an optionally protected or activated thiol, and isolating a compound of formula I SS in the form of a single regioisomer and a single diastereomer from the reaction mixture;

wherein optionally the compound of formula II SS is obtained by epoxidation of the double bond in a compound of formula

wherein R is as defined in claim 6 , and

isolating a compound formula II SS obtained from the reaction mixture.

16. A process for the preparation of a compound of formula I SSS according to claim 8 , comprising

performing oxiran ring opening in a compound of formula

optionally by reaction with an optionally protected or activated thiol, and isolating a compound of formula I SSS in the form of a single regioisomer and a single diastereomer from the reaction mixture;

wherein optionally the compound of formula II SSS is obtained by epoxidation of the double bond in a compound of formula

and

isolating a compound formula II SSS obtained from the reaction mixture.

17. A process for the production of a compound of formula I S according to claim 5 , comprising

a) either reacting a compound of formula

with an azidoyl forming agent, optionally diphenylphosphoryl azide, optionally in the presence of a base, or

reacting compound of formula V with an acid chloride forming agent, optionally oxalyl chloride or thionyl chloride, to obtain a compound of formula IX

and

further reacting a compound of formula IX with sodium azide, to obtain the acyl azide of formula

b) subjecting the acyl azide of formula VI to a Curtius rearrangement to obtain an isocyanate of formula

c) either reacting the isocyanate of step b) either via addition of an alcohol or via reaction with an strong organic acid and optionally in the presence of CuCl, or

subjecting a compound of formula VII to hydrolysis with subsequent loss of carbon dioxide to obtain a compound of formula IV

and

further reacting a compound of formula IV with an amino protecting group, optionally in the presence of base, to obtain a compound of formula III S ,

wherein PROT is an amine protective group,

d) subjecting a compound of formula III S to epoxidation by use of an oxidation agent to obtain a corresponding oxiran of formula II S

wherein PROT is an amine protective group, in solution,

e) subjecting a compound obtained in step d) to oxiran ring opening under introduction of a sulfur group in the side chain of the cyclohexyl ring via a sulfur donating agent, and

f) directly isolating a compound of formula I S according to claim 5 ,

optionally by addition of an appropriate anti solvent,

optionally whereby the reaction a) to e) is performed in a single solvent (system), and/or whereby none of the intermediates obtained in a) to d) is isolated,

and isolating a compound of formula I S in the form of a crystalline solid, from the reaction mixture.

18. A process for the production of a compound of formula I SS according to claim 6 , comprising

a) either reacting a compound of formula

with an azidoyl forming agent, optionally diphenylphosphoryl azide, optionally in the presence of a base, or

reacting compound of formula V with an acid chloride forming agent, optionally oxalyl chloride or thionyl chloride, to obtain a compound of formula IX

and

further reacting a compound of formula IX with sodium azide, to obtain the acyl azide of formula

b) subjecting the acyl azide of formula VI to a Curtius rearrangement to obtain an isocyanate of formula

c) either reacting the isocyanate of step b) either via addition of an alcohol or via reaction with an strong organic acid and optionally in the presence of CuCl, or

subjecting a compound of formula VII to hydrolysis with subsequent loss of carbon dioxide to obtain a compound of formula IV

and

further reacting a compound of formula IV with an amino protecting group, optionally in the presence of base, to obtain a compound of formula III SS ,

wherein R is as defined in claim 6 ,

d) subjecting a compound of formula III SS to epoxidation by use of an oxidation agent to obtain a corresponding oxiran of formula II SS

wherein R is as defined in claim 6 , in solution,

e) subjecting a compound obtained in step d) to oxiran ring opening under introduction of a sulfur group in the side chain of the cyclohexyl ring via a sulfur donating agent, and

f) directly isolating a compound of formula I SS according to claim 6 ,

optionally by addition of an appropriate anti solvent,

optionally whereby the reaction a) to e) is performed in a single solvent (system), and/or whereby none of the intermediates obtained in a) to d) is isolated,

and isolating a compound of formula I SS in the form of a crystalline solid, from the reaction mixture.

19. A process for the production of a compound of formula I SSS according to claim 8 , comprising

a) either reacting a compound of formula

with an azidoyl forming agent, optionally diphenylphosphoryl azide, optionally in the presence of a base, or

reacting compound of formula V with an acid chloride forming agent, optionally oxalyl chloride or thionyl chloride, to obtain a compound of formula IX

and

further reacting a compound of formula IX with sodium azide, to obtain the acyl azide of formula

b) subjecting the acyl azide of formula VI to a Curtius rearrangement to obtain an isocyanate of formula

c) either reacting the isocyanate of step b) either via addition of an alcohol or via reaction with an strong organic acid and optionally in the presence of CuCl, or

subjecting a compound of formula VII to hydrolysis with subsequent loss of carbon dioxide to obtain a compound of formula IV

and

further reacting a compound of formula IV with an amino protecting group, optionally in the presence of base, to obtain a compound of formula III SSS ,

d) subjecting a compound of formula III SSS to epoxidation by use of an oxidation agent to obtain a corresponding oxiran of formula II SSS

e) subjecting a compound obtained in step d) to oxiran ring opening under introduction of a sulfur group in the side chain of the cyclohexyl ring via a sulfur donating agent, and

f) directly isolating a compound of formula I SSS according to claim 8 ,

optionally by addition of an appropriate anti solvent,

optionally whereby the reaction a) to e) is performed in a single solvent (system), and/or whereby none of the intermediates obtained in a) to d) is isolated,

and isolating a compound of formula I SSS in the form of a crystalline solid, from the reaction mixture.

Assignments (11)
NUNC PRO TUNC ASSIGNMENT Recorded Apr 3, 2025
From: NABRIVA THERAPEUTICS GMBH
To: HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
Reel/Frame 070725/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2025
From: NABRIVA THERAPEUTICS GMBH
To: HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
Reel/Frame 069806/0458 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA AND THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 062881 FRAME: 0090. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Jun 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064312/0350 →
RELEASE OF SECURITY INTEREST Recorded Mar 3, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH; ZAVANTE THERAPEUTICS, INC.
Reel/Frame 062881/0090 →
SECURITY INTEREST Recorded Jan 18, 2019
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 048062/0807 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 20, 2018
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0110 →
CHANGE OF NAME Recorded May 17, 2018
From: NABRIVA THERAPEUTICS AG
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 047658/0862 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. IN THE RELEASE BY SECURED PARTY FROM 12/699585 TO 13/699585 PREVIOUSLY RECORDED ON REEL 037093 FRAME 0308. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE AGREEMENT. Recorded Dec 2, 2015
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037190/0424 →
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2015
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037093/0308 →
LIEN Recorded Sep 3, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033659/0216 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2012
From: RIEDL, ROSEMARIE; HEILMAYER, WERNER; SPENCE, LEE; BULUSU, ATCHYUTA RAMA CHANDRA MURTY
To: NABRIVA THERAPEUTICS AG
Reel/Frame 029355/0554 →
Priority Claims (1)
EP 10450093 · May 26, 2010 · regional
Continuity (1)
Related Publication 20130072711A1 · Mar 21, 2013